중앙백신
Financials
Valuation Metrics
중앙백신's Market Cap is ₩849B. At end of 2025 it was ₩907B. Ranked #1374 of 2,421 in KR market (top 57%), #772 of 1,640 on KOSDAQ (top 47%), #148 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 84.88B KRW | KR#1,374/2,421 Sec#148/231 |
| Revenue | 48.28B KRW | KR#1,814/2,421 Sec#126/231 |
| Net Income | 7.99B KRW | KR#1,040/2,421 Sec#64/231 |
| Total Assets | 125.52B KRW | KR#1,618/2,421 Sec#127/231 |
| Net Assets | 108.11B KRW | KR#1,355/2,421 Sec#107/231 |
| Employees | 187 | KR#1,148/2,421 Sec#95/231 |
| Value | ||
| P/E | 10.63x | KR#847/2,421 Sec#44/231 |
| P/B | 0.79x | KR#1,241/2,421 Sec#74/231 |
| PEG | 0.30x | KR#632/2,421 Sec#37/231 |
| P/S | 1.76x | KR#1,731/2,421 Sec#99/231 |
| EV/EBITDA | 11.26x | KR#679/2,421 Sec#35/231 |
| FCF Yield | 2.30% | KR#1,034/2,421 Sec#68/231 |
| Profitability | ||
| ROE | 7.39% | KR#852/2,421 Sec#60/231 |
| ROA | 6.36% | KR#586/2,421 Sec#47/231 |
| Op. Margin | 14.15% | KR#328/2,421 Sec#30/231 |
| Revenue Growth | 2.18% | KR#1,374/2,421 Sec#135/231 |
| Earnings Growth | 35.38% | KR#618/2,421 Sec#41/231 |
| Financial Health | ||
| Debt Ratio | 16.10% | KR#278/2,421 Sec#41/231 |
| Total Debt | 6.17B KRW | KR#1,747/2,421 Sec#165/231 |
| FCF | 1.95B KRW | KR#1,086/2,421 Sec#78/231 |
| Cash | 14.14B KRW | KR#1,477/2,421 Sec#120/231 |
| Current Ratio | 4.31x | KR#346/2,421 Sec#54/231 |
| Net Debt/EBITDA | -1.17x | KR#344/2,421 Sec#17/231 |
| Dividend | ||
| Div. Yield | 2.17% | KR#839/2,421 Sec#43/231 |
| Div. Growth | 17.65% | KR#478/2,421 Sec#26/231 |
| Performance | ||
| 1Y Return | -7.37% | KR#895/2,421 Sec#53/231 |
| 1M Return | -0.33% | KR#1,278/2,421 Sec#97/231 |
| From 52W High | -11.40% | KR#91/2,421 Sec#5/231 |
| 1Y MDD | -12.90% | KR#10/2,421 Sec#1/231 |
| Trading | ||
| Volume | 8,527 shares | KR#1,980/2,421 Sec#190/231 |
| Trading Value | 78.4M KRW | KR#1,663/2,421 Sec#168/231 |
| Foreign Own. | 2.53% | KR#1,447/2,421 Sec#135/231 |
| Per Share | ||
| EPS | 863 KRW | KR#781/2,421 Sec#55/231 |
| BPS | 11,679 KRW | KR#879/2,421 Sec#61/231 |
Company Info
Joongang Vaccine was established in 1968 as a private enterprise, converted to a corporation in 1994, and listed on KOSDAQ in 2003. Headquartered in Yuseong-gu, Daejeon, it manufactures about 80 types of animal vaccines for disease prevention, selling them to farms, distributors, and animal hospitals, and provides feed additive sales, rabies testing, disease diagnosis, and research services for biological products. With strengthened antibiotic regulations, the focus is shifting from treatment to prevention, increasing demand for animal vaccines, and the company is developing new markets in Southeast Asia, South America, and China.